London, UK; Brentwood, TN, US; 18 September 2006 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that it has submitted a Biological License Application ("BLA") to the Food and Drug Administration ("FDA") in the US for Voraxaze™. Voraxaze™ is an adjunctive therapy for patients experiencing or at risk of toxicity from methotrexate ("MTX"), a widely used anti-cancer agent. Patients are considered at risk of MTX toxicity if they have impaired renal function, which can lead to a delay in MTX elimination, or have evidence of delayed elimination based on MTX levels.
